EE03489B1 - Olansapiini polümorfne vorm II, selle saamismeetod ja farmatseutiline preparaat - Google Patents

Olansapiini polümorfne vorm II, selle saamismeetod ja farmatseutiline preparaat

Info

Publication number
EE03489B1
EE03489B1 EE9700232A EE9700232A EE03489B1 EE 03489 B1 EE03489 B1 EE 03489B1 EE 9700232 A EE9700232 A EE 9700232A EE 9700232 A EE9700232 A EE 9700232A EE 03489 B1 EE03489 B1 EE 03489B1
Authority
EE
Estonia
Prior art keywords
preparation
olanzapine
polymorphic form
pharmaceutical preparation
pharmaceutical
Prior art date
Application number
EE9700232A
Other languages
English (en)
Other versions
EE9700232A (et
Inventor
Arthur Bunnell Charles
Arnold Hendriksen Barry
Dean Larsen Samuel
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03489(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of EE9700232A publication Critical patent/EE9700232A/et
Publication of EE03489B1 publication Critical patent/EE03489B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
EE9700232A 1995-03-24 1996-03-22 Olansapiini polümorfne vorm II, selle saamismeetod ja farmatseutiline preparaat EE03489B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Publications (2)

Publication Number Publication Date
EE9700232A EE9700232A (et) 1998-04-15
EE03489B1 true EE03489B1 (et) 2001-08-15

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700232A EE03489B1 (et) 1995-03-24 1996-03-22 Olansapiini polümorfne vorm II, selle saamismeetod ja farmatseutiline preparaat

Country Status (49)

Country Link
US (1) US5736541A (et)
EP (3) EP1445259B1 (et)
JP (1) JPH11502535A (et)
KR (1) KR100399688B1 (et)
CN (1) CN1065536C (et)
AP (1) AP828A (et)
AR (2) AR002719A1 (et)
AT (4) AT406771B (et)
AU (1) AU706471B2 (et)
BG (1) BG62619B1 (et)
BR (1) BR9607790A (et)
CA (1) CA2214005C (et)
CH (1) CH690579A5 (et)
CO (1) CO4650278A1 (et)
CZ (1) CZ292688B6 (et)
DE (4) DE69636313T2 (et)
DK (4) DK0733635T3 (et)
EA (1) EA000149B1 (et)
EE (1) EE03489B1 (et)
EG (1) EG23659A (et)
ES (3) ES2208220T3 (et)
FI (1) FI973750A (et)
GB (1) GB2313835B (et)
HK (1) HK1013988A1 (et)
HU (1) HU224989B1 (et)
IL (1) IL117610A (et)
IS (1) IS1896B (et)
LT (1) LT4349B (et)
LU (1) LU90096B1 (et)
LV (1) LV12018B (et)
MY (1) MY114701A (et)
NO (1) NO314663B1 (et)
NZ (1) NZ306110A (et)
OA (1) OA10510A (et)
PA (1) PA8353701A1 (et)
PE (1) PE44897A1 (et)
PL (1) PL183723B1 (et)
PT (3) PT1095941E (et)
RO (1) RO118872B1 (et)
SE (1) SE9703205D0 (et)
SI (4) SI9620040B (et)
SK (1) SK284143B6 (et)
SV (1) SV1996000031A (et)
TR (1) TR199701017T1 (et)
TW (2) TW442488B (et)
UA (1) UA44765C2 (et)
WO (1) WO1996030375A1 (et)
YU (1) YU49478B (et)
ZA (2) ZA962342B (et)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US6274636B1 (en) * 1995-09-29 2001-08-14 Eli Lilly And Company Method for treating a tic disorder
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
TR199801800T2 (xx) * 1996-03-11 1998-12-21 Eli Lilly And Company Uykusuzluk tedavisi.
JP2000507546A (ja) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 麻酔方法
BR9708246A (pt) * 1996-03-25 1999-07-27 Lilly Co Eli Metodo para tratamento de dor
CZ296263B6 (cs) * 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
IL126063A (en) * 1996-03-25 2002-04-21 Lilly Co Eli Medicinal products containing ulanzapine for the treatment of migraine pain
ID21924A (id) * 1996-09-23 1999-08-12 Lilly Co Eli Olanzapin dihidrat d
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
EP1155696B1 (en) * 1997-04-15 2004-03-03 Eli Lilly And Company Use of olanzapine for the manufacture of a medicament for neuroprotection
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
DE69917663T2 (de) * 1998-09-30 2005-05-25 Eli Lilly And Co., Indianapolis 2-methyl-thieno-benzodiazepin-formulierung
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
AU779452B2 (en) * 1999-12-28 2005-01-27 Cipla Limited New polymorphic forms of olanzapine
JP2004507548A (ja) * 2000-08-31 2004-03-11 ドクター・レディーズ・ラボラトリーズ・リミテッド オランザピン水和物の調製方法、及びこれを結晶形態のオランザピンに変換する方法
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
AU2002340328A1 (en) * 2001-10-29 2003-05-12 Janet I. Cord Olanzapine dihydrate-ii a process for its preparation and use thereof
CH695862A5 (fr) 2001-12-24 2006-09-29 Sun Pharmaceutical Ind Ltd Forme cristalline I de la methyl-4-(4-methyl-1-piperazinyl) 10H-thieno [2,3-b] [1,5] benzodiazepine.
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
ATE500258T1 (de) 2002-05-31 2011-03-15 Sandoz Ag Verfahren zur herstellung von olanzapin form i
MXPA05000232A (es) * 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
EP1575962A1 (en) 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
US20040242619A1 (en) * 2003-03-12 2004-12-02 Toth Zoltan G. Processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
EP1611139B1 (en) * 2003-12-22 2008-06-04 Teva Pharmaceutical Industries Ltd. Methods of preparing olanzapine
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
ES2303462B1 (es) * 2004-09-06 2009-06-05 Shasun Chemicals And Drugs Limited Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
JP5324098B2 (ja) * 2004-11-16 2013-10-23 アルケルメス ファーマ アイルランド リミテッド 注射可能なナノ粒子のオランザピン製剤
US7932249B2 (en) 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
WO2006102176A2 (en) * 2005-03-21 2006-09-28 Dr. Reddy's Laboratories Ltd. Process for preparing crystalline form i of olanzapine
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
HUE041981T2 (hu) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
CA2882596C (en) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine and use thereof
CN108517014A (zh) 2012-08-21 2018-09-11 詹森药业有限公司 利培酮半抗原的抗体及其用途
TR201910347T4 (tr) * 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (en) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof
US20240238308A1 (en) 2023-01-10 2024-07-18 Medincell Sa Olanzapine compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
DE69329887T2 (de) * 1992-05-29 2001-05-23 Eli Lilly And Co., Ltd. Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
HK1013988A1 (en) 1999-09-17
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
EP1445259B1 (en) 2006-06-28
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
YU49478B (sh) 2006-05-25
CN1179160A (zh) 1998-04-15
EA000149B1 (ru) 1998-10-29
DE69636313T2 (de) 2007-05-31
CA2214005C (en) 2001-07-03
ES2208220T3 (es) 2004-06-16
CO4650278A1 (es) 1998-09-03
LV12018B (en) 1998-09-20
LU90096B1 (fr) 1997-07-22
EP1095941B1 (en) 2003-10-08
HUP9802824A2 (hu) 1999-06-28
LT4349B (lt) 1998-05-25
ES2266719T3 (es) 2007-03-01
US5736541A (en) 1998-04-07
AU5427996A (en) 1996-10-16
MX9707183A (es) 1997-11-29
BG101900A (en) 1999-03-31
IL117610A (en) 2001-08-26
DE69614426D1 (de) 2001-09-20
FI973750A0 (fi) 1997-09-22
HUP9802824A3 (en) 2000-01-28
UA44765C2 (uk) 2002-03-15
SI9620040A (sl) 1998-06-30
PL183723B1 (pl) 2002-07-31
DE69630324T2 (de) 2004-07-29
AT406771B (de) 2000-08-25
DE69614426T2 (de) 2002-05-23
IS4564A (is) 1997-09-22
EE9700232A (et) 1998-04-15
GB9719819D0 (en) 1997-11-19
HU224989B1 (en) 2006-05-29
EG23659A (en) 2007-03-26
KR19980703188A (ko) 1998-10-15
OA10510A (en) 2002-04-24
TW513432B (en) 2002-12-11
ATE204280T1 (de) 2001-09-15
CH690579A5 (de) 2000-10-31
SV1996000031A (es) 1998-03-27
ES2159346T3 (es) 2001-10-01
SI9620040B (sl) 2002-02-28
GB2313835A (en) 1997-12-10
IL117610A0 (en) 1996-07-23
DK108997A (da) 1997-11-12
TW442488B (en) 2001-06-23
AP828A (en) 2000-04-28
LT97148A (en) 1998-01-26
CN1065536C (zh) 2001-05-09
EP1445259A1 (en) 2004-08-11
BR9607790A (pt) 1998-07-07
SI1445259T1 (sl) 2006-10-31
ATE331719T1 (de) 2006-07-15
SK284143B6 (sk) 2004-10-05
LV12018A (lv) 1998-04-20
RO118872B1 (ro) 2003-12-30
EP0733635B1 (en) 2001-08-16
SI0733635T1 (en) 2002-06-30
CZ300097A3 (en) 1997-12-17
MY114701A (en) 2002-12-31
SE9703205L (sv) 1997-09-05
YU17796A (sh) 1999-03-04
DE19681286T1 (de) 1998-04-02
CZ292688B6 (cs) 2003-11-12
BG62619B1 (bg) 2000-03-31
SE9703205D0 (sv) 1997-09-05
AR002719A1 (es) 1998-04-29
NO314663B1 (no) 2003-04-28
DE69630324D1 (de) 2003-11-13
KR100399688B1 (ko) 2004-02-18
NZ306110A (en) 1998-09-24
DE69636313D1 (de) 2006-08-10
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
JPH11502535A (ja) 1999-03-02
ATE251627T1 (de) 2003-10-15
CA2214005A1 (en) 1996-10-03
EA199700262A1 (ru) 1998-02-26
SI1095941T1 (en) 2003-12-31
DK0733635T3 (da) 2001-10-08
AU706471B2 (en) 1999-06-17
FI973750A (fi) 1997-09-22
SK121897A3 (en) 1998-03-04
TR199701017T1 (xx) 1998-01-21
ZA962342B (en) 1997-09-22
EP0733635A1 (en) 1996-09-25
DK1445259T3 (da) 2006-10-16
ATA902196A (de) 2000-01-15
PT733635E (pt) 2001-12-28
PT1095941E (pt) 2004-02-27
ZA962344B (en) 1997-09-22
EP1095941A1 (en) 2001-05-02
PE44897A1 (es) 1997-10-22
NO974365L (no) 1997-09-22
PL322501A1 (en) 1998-02-02
DK1095941T3 (da) 2004-02-16
IS1896B (is) 2003-10-20
GB2313835B (en) 1998-09-16

Similar Documents

Publication Publication Date Title
EE03489B1 (et) Olansapiini polümorfne vorm II, selle saamismeetod ja farmatseutiline preparaat
EE9900296A (et) Suure bioomastatavusega fenofibraatide ravimkoostis ja meetod selle valmistamiseks
EE03263B1 (et) Erütromütsiini derivaadid, nende valmistamismeetod, farmatseutiline kompositsioon ja vaheühendid
NO962750L (no) Fremgangsmåte for fremstilling av buten-1
NO20000227L (no) Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat, fremgangsmåte for dens fremstilling og dens anvendelse
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
NO970293D0 (no) Substituerte camptotecinderivater og fremgangsmåte for dens fremstilling
NO991382D0 (no) Mellomprodukter og fremgangsmÕte for fremstilling av olanzapin
FI950625A (fi) Polysubstituoituja 3-asyyliamino-5-fenyyli-1,4-bentsodiatsepiini-2-onijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
EE03351B1 (et) Meetod lerkanidipiinhüdrokloriidi valmistamiseks
NO982237L (no) FremgangsmÕte for fremstilling av fenylimidazolidinderivater
EE200100173A (et) 2-fenüülpüraan-4-ooni derivaadid, nende valmistamismeetod ja kasutamine, vaheühendite kasutamine jafarmatseutiline kompositsioon
NO961252D0 (no) Fremgangsmåte for fremstilling av N-metyl-3-(1-metyl-4-piperidinyl)-14-indol-5-etansulfonamid
FI960937A (fi) Menetelmä aryylialkyylihydroperoksidien valmistamiseksi
EE9900385A (et) Zopolrestaat-monohüdraadi polümorfne vorm, selle kasutamine ja valmistamise protsess
ID24527A (id) Proses pembuatan senyawa-senyawa farmasi
NO20001777D0 (no) Fremgangsmåte for fremstilling av substituerte 4-fenyl-4- cyanocykloheksankarboksylsyrer
NO981537L (no) FremgangsmÕte for fremstilling av antimalariamedikamenter
EE200000336A (et) Ehhinokandiini derivaadid, nende valmistamismeetod, vaheühendid ja farmatseutilised kompositsioonid
NO993845D0 (no) Fremgangsmåte for fremstilling av smörsyrederivater
NO974846D0 (no) Fremgangsmåte for fremstilling av Form 1 Ranitidin-Hydroklorid
FR2733236B1 (fr) Procede de preparation de streptogramines
FR2763942B1 (fr) Nouveau procede de preparation de n-acylaminoacides
NO982090D0 (no) FremgangsmÕte for fremstilling av 3-fenyl-1-metylendioksyfenyl-indan-2-karboksylsyrederivater

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20140322